# Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

> **NCT02318329** · PHASE1 · COMPLETED · sponsor: **Five Prime Therapeutics, Inc.** · enrollment: 79 (actual)

## Conditions studied

- Advanced Solid Tumors
- Gastric Cancer
- Transitional Cell Carcinoma of the Bladder

## Interventions

- **DRUG:** FPA144

## Key facts

- **NCT ID:** NCT02318329
- **Lead sponsor:** Five Prime Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2019-02-28
- **Final completion:** 2019-06-30
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2024-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02318329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02318329, "Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02318329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*